Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Liabilities and Shareholders Equity (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Liabilities and Shareholders Equity readings, the most recent being $17.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 49.31% year-over-year to $17.7 million, compared with a TTM value of $93.6 million through Dec 2025, down 42.9%, and an annual FY2025 reading of $17.7 million, down 49.31% over the prior year.
  • Liabilities and Shareholders Equity hit $17.7 million in Q4 2025 for Lisata Therapeutics, down from $21.8 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $66.3 million in Q1 2023, with the low at $17.7 million in Q4 2025.
  • Median Liabilities and Shareholders Equity over the past 3 years was $40.4 million (2024), compared with a mean of $41.6 million.
  • The sharpest move saw Liabilities and Shareholders Equity fell 27.27% in 2024, then crashed 49.31% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $54.7 million in 2023, then tumbled by 36.0% to $35.0 million in 2024, then tumbled by 49.31% to $17.7 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $17.7 million, $21.8 million, and $25.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.